Keytruda

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

The FDA initially approved Keytruda in 2017 for stomach cancer based on overall response rate data. ... Among these, Keytruda achieved an overall response rate of just over 13% (19 patients), with a complete response rate of 1.4%.

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies

Instead of targeting a specific genetic defect, Keytruda targets tumours that have a high degree of genetic instability. ... As Vitrakvi and Rozlytrek lead with their TA indications, the challenges faced by these therapies are wholly different to Keytruda

Merck’s Keytruda improves outcomes for metastatic cervical cancer patients

Keytruda improved overall survival and progression-free survival regardless of patients' PD-L1 status. ... Merck – known as MSD outside the US and Canada – has revealed positive results for its checkpoint inhibitor Keytruda in patients with persistent

Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients

Merck &Co – known as MSD outside the US and Canada – has announced that its PD-1 inhibitor Keytruda plus Eisai’s Lenvima improved outcomes versus Pfizer’s Sutent on a measure ... When administered alongside Lenvima, Keytruda demonstrated a

Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients

dominant shadow of Merck &Co’s Keytruda (pembrolizumab).

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]